FDA Approval of Orforglipron Broadens Access to Obesity Treatment and Oral GLP-1 Therapy

In this Pharmacy Times interview, Richard Frank, MD, MHSA, chief medical officer at Vida Health, discusses the clinical and practical implications of the FDA approval of orforglipron for obesity and cardiometabolic disease management. Frank explains that the oral glucagon-like peptide-1 receptor agonist may help address barriers associated with injectable therapies, including needle aversion, refrigeration requirements, and complicated administration instructions. He also notes that oral therapies like orforglipron could support earlier treatment initiation and offer additional flexibility in long-term obesity care strategies. Further, Frank emphasizes that pharmacists and health systems play an important role in optimizing therapy, managing adverse effects, and reinforcing lifestyle interventions alongside pharmacologic treatment.